You are seeing these quotes based on previous browsing related to sectors such as
| Latest | Forecast | |
|---|---|---|
| Div Yield | 0.0% | 0.0% |
| Div Cover | n/a | n/a |
| Op Mrgn | -1,417.5% | -363.0% |
| ROCE | 0.0% |
| Latest | Forecast | |
|---|---|---|
| P/E | -5.4 | 0.0 |
| PEG | 0.0 | -999,999.0 |
| Price / Revenue | 123.0 | 27.4 |
| Price / Book value | 4.9 |
| Latest | Forecast | |
|---|---|---|
| Revenue | 26.0% | 0.0% |
| PBT | 0.0% | n/a |
| EPS | 0.0% | 0.0% |
| DPS | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2014-04-30 | n/a | -2.20 | -4.87p | -17.9 | 0.0 | n/a | n/a | 0.0% |
| 2015-04-30 | n/a | -3.87 | -8.12p | -11.6 | 0.0 | n/a | n/a | 0.0% |
| 2016-04-30 | 0.36 | -5.43 | -8.69p | -7.8 | 0.0 | n/a | n/a | 0.0% |
| 2017-04-30 | 0.50 | -7.41 | -8.95p | -5.8 | 0.0 | n/a | n/a | 0.0% |
| 2018-04-30 | 0.63 | -8.93 | -10.09p | -4.7 | 0.0 | n/a | n/a | 0.0% |
| Year Ending | Revenue (£m) |
Pre-tax (£m) |
EPS | P/E | PEG | EPS Growth | Div | Yield |
|---|---|---|---|---|---|---|---|---|
| 2019-04-30 | 1.30 | -10.30 | -6.40p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2020-04-30 | 2.70 | -9.80 | -6.10p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| 2021-04-30 | 6.40 | -7.00 | -4.20p | 0.0 | n/a | 0% | 0.00p | 0.0% |
| Angle completes enrolment in Parsortix breast cancer study Sharecast News | 07 Mar |
|---|---|
| Angle client demonstrates new use for 'Parsortix' system Sharecast News | 25 Feb |
| Angle's 'Parsortix' used in new groundbreaking cancer research Sharecast News | 11 Feb |
| Holding(s) in Company | 11-Mar-19 07:05 |
|---|---|
| ENROLMENT COMPLETE FOR FDA CLINICAL STUDY | 07-Mar-19 07:04 |
| FIRST SUBJECTS ENROLLED IN OVARIAN CANCER STUDY | 28-Feb-19 07:08 |
| CUSTOMER DEMONSTRATES NEW USE FOR PARSORTIX | 25-Feb-19 07:03 |
| Research into role of immune cells in cancer | 11-Feb-19 07:04 |